Commonground
Senior Moderator
Ends/Wednesday, June 18, 2025
New York ETO promotes biotechnology and academic ties with Boston (with photos)
************************************************** *****************
The Director of the Hong Kong Economic and Trade Office in New York, Ms Maisie Ho, visited Boston, Massachusetts, from June 15 to 17 (Boston time) to foster closer ties with the city's biotechnology, research, and academic sectors. During her visit, she attended the BIO International Convention (BIO 2025), one of the world's leading global biotechnology event.
At the June 15 (Boston time) welcome dinner for the Hong Kong delegation at BIO 2025, Ms Ho highlighted Hong Kong’s status as a global hub for biotech innovation and fundraising. She also noted Hong Kong's strong presence at BIO 2025, showcasing the depth and diversity of the city's biotechnology sector, including pharmaceuticals, immunotherapies, gene editing, diagnostics and stem cell technologies.
The Hong Kong delegation included representatives from the Hong Kong Science and Technology Parks Corporation and its delegation of 16 leading biotech portfolio companies, the medical faculties of the University of Hong Kong and the Chinese University of Hong Kong, as well as representatives from the Office for Attracting Strategic Enterprises, Invest Hong Kong and the Hong Kong Trade Development Council. At the Hong Kong Pavilion, they showcased the city's life and health sciences capabilities, aiming to attract global enterprises, talent, and investment, and reinforcing Hong Kong's status as a global biotech hub.
At the "Hong Kong x Boston Biotech Disrupt Night" on June 16 (Boston time) hosted by Invest Hong Kong, Ms Ho spoke on Hong Kong's strategic advantages in biotechnology, citing world-class infrastructure, strong intellectual property protection, top-tier universities, and a vibrant start-up ecosystem. She also emphasised government support, funding and initiatives such as InnoLife Healthtech Hub and the New Industrialisation Acceleration Scheme. The event, attended by over 140 biotech industry representatives and investors, also featured a panel discussion featuring Hong Kong and Boston's biotech leaders where they had an insightful exchange on the potential of Boston biotech companies in leveraging Hong Kong for their Asian market expansion.
"Hong Kong offers a nurturing environment for life sciences—combining policy support, research excellence, and regulatory certainty. As the world's second-largest fundraising hub for biotech IPOs, we also offer deep access to capital and a highly international talent pool. With our world-class infrastructure, common law system, robust IP protections, and proximity to Mainland China and Asia, we serve as a gateway and global launchpad for biotech companies aiming to scale and internationalise", she said.
While in Boston, Ms Ho also met with representatives of the academia to explore areas of mutual interests and promoted Hong Kong's various talent admission schemes and the city's commitment to become an international education and research hub. Her meetings included discussions with Visiting Fellow of Practice at Harvard University's Fairbank Center for Chinese Studies Mr Mitchell Presnick; and representatives from the University of Massachusetts Boston, including the Provost and Vice Chancellor for Academic Affairs, Mr Joseph B. Berger; the Vice Chancellor for Student Affairs, Ms Karen Ferrer-Muñiz; and the Vice Provost of Research and Strategic Initiatives, Mr Bala Sundaram. She also attended a reception hosted by the Mayor of Boston Ms Michelle Wu for key international biotech leaders and stakeholders.
https://www.info.gov.hk/gia/general/202506/18/P2025061800046.htm
New York ETO promotes biotechnology and academic ties with Boston (with photos)
************************************************** *****************
The Director of the Hong Kong Economic and Trade Office in New York, Ms Maisie Ho, visited Boston, Massachusetts, from June 15 to 17 (Boston time) to foster closer ties with the city's biotechnology, research, and academic sectors. During her visit, she attended the BIO International Convention (BIO 2025), one of the world's leading global biotechnology event.
At the June 15 (Boston time) welcome dinner for the Hong Kong delegation at BIO 2025, Ms Ho highlighted Hong Kong’s status as a global hub for biotech innovation and fundraising. She also noted Hong Kong's strong presence at BIO 2025, showcasing the depth and diversity of the city's biotechnology sector, including pharmaceuticals, immunotherapies, gene editing, diagnostics and stem cell technologies.
The Hong Kong delegation included representatives from the Hong Kong Science and Technology Parks Corporation and its delegation of 16 leading biotech portfolio companies, the medical faculties of the University of Hong Kong and the Chinese University of Hong Kong, as well as representatives from the Office for Attracting Strategic Enterprises, Invest Hong Kong and the Hong Kong Trade Development Council. At the Hong Kong Pavilion, they showcased the city's life and health sciences capabilities, aiming to attract global enterprises, talent, and investment, and reinforcing Hong Kong's status as a global biotech hub.
At the "Hong Kong x Boston Biotech Disrupt Night" on June 16 (Boston time) hosted by Invest Hong Kong, Ms Ho spoke on Hong Kong's strategic advantages in biotechnology, citing world-class infrastructure, strong intellectual property protection, top-tier universities, and a vibrant start-up ecosystem. She also emphasised government support, funding and initiatives such as InnoLife Healthtech Hub and the New Industrialisation Acceleration Scheme. The event, attended by over 140 biotech industry representatives and investors, also featured a panel discussion featuring Hong Kong and Boston's biotech leaders where they had an insightful exchange on the potential of Boston biotech companies in leveraging Hong Kong for their Asian market expansion.
"Hong Kong offers a nurturing environment for life sciences—combining policy support, research excellence, and regulatory certainty. As the world's second-largest fundraising hub for biotech IPOs, we also offer deep access to capital and a highly international talent pool. With our world-class infrastructure, common law system, robust IP protections, and proximity to Mainland China and Asia, we serve as a gateway and global launchpad for biotech companies aiming to scale and internationalise", she said.
While in Boston, Ms Ho also met with representatives of the academia to explore areas of mutual interests and promoted Hong Kong's various talent admission schemes and the city's commitment to become an international education and research hub. Her meetings included discussions with Visiting Fellow of Practice at Harvard University's Fairbank Center for Chinese Studies Mr Mitchell Presnick; and representatives from the University of Massachusetts Boston, including the Provost and Vice Chancellor for Academic Affairs, Mr Joseph B. Berger; the Vice Chancellor for Student Affairs, Ms Karen Ferrer-Muñiz; and the Vice Provost of Research and Strategic Initiatives, Mr Bala Sundaram. She also attended a reception hosted by the Mayor of Boston Ms Michelle Wu for key international biotech leaders and stakeholders.
https://www.info.gov.hk/gia/general/202506/18/P2025061800046.htm